What is the recommended intramuscular dose of Buscopan (hyoscine butylbromide) in adults, its indications, contraindications, and precautions?

Intramuscular Buscopan (Hyoscine Butylbromide) Administration

For intramuscular administration in adults, Buscopan (hyoscine butylbromide) is given at a dose of 20 mg (1 mL of 20 mg/mL solution), which can be repeated as needed for severe abdominal cramping and gastrointestinal spasms. 1, 2

Indications for IM Buscopan

• Abdominal pain associated with gastrointestinal cramping and spasms where oral administration is not feasible or effective 1, 3
• Severe or refractory abdominal pain requiring parenteral administration 3
• Intestinal dysmotility with significant cramping 1
• IM preparations may be more effective than oral forms due to poor oral bioavailability (<1%) of hyoscine butylbromide 2

Dosing Specifications

• Standard adult IM dose: 20 mg (1 mL) as a single injection 1, 2
• Can be repeated based on clinical response and symptom severity 2
• IM route provides better systemic availability compared to oral administration, which has bioavailability <1% 2
• The drug has high tissue affinity for muscarinic receptors at the site of action in the intestine 2

Absolute Contraindications

Cardiac conditions requiring extreme caution or avoidance:

• Tachycardia - Buscopan is contraindicated according to product monograph 4
• Angina pectoris - contraindicated per product labeling 4
• Cardiac failure - contraindicated per product labeling 4

Other absolute contraindications:

• Prostatic hypertrophy with urinary retention - contraindicated per product monograph 4

Critical Precautions and Monitoring

Cardiac monitoring is essential:

• Patients with any cardiac comorbidities require careful cardiac monitoring during and after administration 3, 4
• Cardiac complications are more clinically significant than ophthalmic complications 3
• Administration should only occur in environments where resuscitation equipment and appropriately trained staff are readily available 4

Risk-benefit assessment required:

• In patients with contraindicated conditions, use only when potential benefits clearly outweigh risks 4
• This requires explicit clinical judgment on a case-by-case basis 4

Mechanism and Clinical Pharmacology

• Hyoscine butylbromide is a quaternary ammonium antimuscarinic agent that blocks muscarinic receptors on GI smooth muscle 2, 5
• It also blocks nicotinic acetylcholine receptors, producing a ganglion-blocking effect that contributes to spasmolytic activity 2, 6
• The drug does not cross the blood-brain barrier due to its quaternary structure, minimizing central nervous system effects 2
• High tissue affinity for muscarinic receptors allows local spasmolytic effect despite low systemic bioavailability 2

Post-Administration Counseling

Patients should be instructed to seek emergency care if they develop:

• Eye pain or redness 4
• Decreased vision 4
• Nausea and vomiting (in context of visual symptoms) 4
• Severe headache (in context of visual symptoms) 4

These symptoms could indicate acute angle-closure glaucoma, though this risk is lower than cardiac complications 4.

Common Pitfalls to Avoid

• Do not use in patients with documented tachycardia, angina, or heart failure without explicit consideration that benefits outweigh substantial risks 4
• Do not assume glaucoma history is the primary concern - cardiac monitoring takes precedence 3, 4
• Do not use IM route when oral administration is adequate - reserve parenteral route for severe or refractory cases 3
• Ensure resuscitation capabilities are immediately available before administration in any patient with cardiac risk factors 4